
Tenaya Therapeutics, Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
Tenaya Therapeutics is a biotechnology company developing therapies for heart disease, including gene therapies for genetic cardiomyopathies, cellular regeneration treatments to restore heart muscle after injury, and precision medicines targeting disease-causing genetic variants.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Ali FarazChief Executive Officer | Sell | $5K | 7,406at $0.71 | Aug 17, 2026 |
| Ali FarazChief Executive Officer | Sell | $4K | 5,837at $0.71 | Aug 17, 2026 |
| Ali FarazChief Executive Officer | Sell | $4K | 5,020at $0.71 | Aug 17, 2026 |
| Ali FarazChief Executive Officer | Sell | $3K | 3,969at $0.71 | Aug 17, 2026 |
| Tingley WhittemoreChief Medical Officer | Sell | $2K | 2,279at $0.71 | Aug 17, 2026 |
| Tingley WhittemoreChief Medical Officer | Sell | $1K | 1,871at $0.71 | Aug 17, 2026 |
| Tingley WhittemoreChief Medical Officer | Sell | $1K | 1,637at $0.71 | Aug 17, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable TNYA activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.